Effect of tumor necrosis factor-α antagonism in asthma: a meta-analysis of the published literature

Abstract

It remains controversial whether tumor necrosis factor (TNF)-α antagonism is effective for asthma. This meta-analysis was performed to evaluate efficacy of TNF-α antagonism in treatment of patients with asthma. MEDLINE, EMBASE, LILACS, and CINAHL databases were searched for English-language studies published through January 3, 2010. Randomized-controlled trials comparing TNF-α antagonism with control therapy were selected. For each report, data were extracted in relation to the outcomes analyzed: asthma exacerbation, asthma quality of life questionnaire scores, and forced expiratory volume in 1 second. Four assessable trials were identified including 641 patients with asthma. TNF-α antagonism therapy was superior to control therapy in preventing exacerbations in asthmatics [pooled odds ratio 0.52 (95% confidence interval 0.29–0.88), P=0.02]; however, there was a nonsignificant reduction in asthma quality of life questionnaire scores [0.23 (0 to 0.47), P=0.05], forced expiratory volume in 1 second [0.03, (−0.14 to 0.10), P=0.74] when analyzed using standardized mean differences. TNF-α antagonism was superior to control chemotherapy in terms of asthma exacerbation, but not asthma quality of life questionnaire scores or forced expiratory volume in 1 second.

Keywords

asthma / immunotherapy / Meta-analysis / tumor necrosis factor-α

References

[1] FantaC.H.. Asthma. N Engl J Med, 2009, 360(10): 1002-1014

[2] ItoK., ChungK.F., AdcockI.M.. Update on glucocorticoid action and resistance. J Allergy Clin Immunol, 2006, 117(3): 522-543

[3] WenzelS., SzeflerS.J.. Managing severe asthma. J Allergy Clin Immunol, 2006, 117(3): 508-511

[4] The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma.. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J, 2003, 22(3): 470-477

[5] MooreW.C., BleeckerE.R., Curran-EverettD., et al.. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol, 2007, 119(2): 405-413

[6] CooksonW., MoffattM.. Making sense of asthma genes. N Engl J Med, 2004, 351(17): 1794-1796

[7] GaoJ., ShanG., SunB., et al.. Association between polymorphism of tumour necrosis factor alpha-308 gene promoter and asthma: a meta-analysis. Thorax, 2006, 61(6): 466-471

[8] Cembrzynska-NowakM., SzklarzE., InglotA.D., et al.. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis, 1993, 147(2): 291-295

[9] ObaseY., ShimodaT., MitsutaK., et al.. Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum. Ann Allergy Asthma Immunol, 2001, 86(3): 304-310

[10] ThomasP.S., YatesD.H., BarnesP.J.. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med, 1995, 152(1): 76-80

[11] ThomasP.S., HeywoodG.. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax, 2002, 57(9): 774-778

[12] HowarthP.H., BabuK.S., ArshadH.S., et al.. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax, 2005, 60(12): 1012-1018

[13] RouhaniF.N., MeitinC.A., KalerM., et al.. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med, 2005, 99(9): 1175-1182

[14] RobinsonK.A., DickersinK.. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol, 2002, 31(1): 150-153

[15] JadadA.R., MooreR.A., CarrollD., et al.. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials, 1996, 17(1): 1-12

[16] SchulzK.F., ChalmersI., HayesR.J., et al.. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA, 1995, 273(5): 408-412

[17] DerSimonianR., LairdN.. Meta-analysis in clinical trials. Control Clin Trials, 1986, 7(3): 177-188

[18] DeeksJ.J., AltmanD., BradburnM.J.. EggerM., Davey SmithG., AltmanD.G.. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic reviews in health care, 2001, London, UK, BMJ Publishing, 285-312

[19] HigginsJ.P., ThompsonS.G., DeeksJ.J., et al.. Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414): 557-560

[20] CurtinF., AltmanD.G., ElbourneD.. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Stat Med, 2002, 21(15): 2131-2144

[21] BerryM.A., HargadonB., ShelleyM., et al.. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med, 2006, 354(7): 697-708

[22] ErinE.M., LeakerB.R., NicholsonG.C., et al.. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med, 2006, 174(7): 753-762

[23] MorjariaJ.B., ChauhanA.J., BabuK.S., et al.. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax, 2008, 63(7): 584-591

[24] WenzelS.E., BarnesP.J., BleeckerE.R., et al.. T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med, 2009, 179(7): 549-558

[25] Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA), 2008. (Accessed August 23, 2009, at http://www.ginasthma.org.)

[26] TantisiraK.G., LakeS., SilvermanE.S., et al.. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet, 2004, 13(13): 1353-1359

[27] LazarusS.C., ChinchilliV.M., RollingsN.J., et al.. National Heart Lung and Blood Institute’s Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med, 2007, 175(8): 783-790

[28] RodrigoG.J., RodrigoC., HallJ.B.. Acute asthma in adults: a review. Chest, 2004, 125(3): 1081-1102

[29] WeissK.B., SullivanS.D.. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol, 2001, 107(1): 3-8

[30] HaraouiB.. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum, 2005, 34(5Suppl1): 7-11